A research study highlighting the powerful potential of human papillomavirus (HPV) vaccines drew upon the work of the Iowa Cancer Registry and is being celebrated as one of 2015’s major achievements in clinical cancer research by the American Society of Clinical Oncology.
The research study, co-authored by University of Iowa professor of epidemiology Dr. Charles Lynch and published in the Journal of the National Cancer Institute, found that widespread HPV vaccination with Gardasil or Cervarix could prevent as many as 25,000 HPV-related cancers per year in the United States alone. These include the majority of invasive cervical, anal, oropharyngeal, and vaginal cancers, as well as some other genital cancers. The Gardasil 9 vaccine could prevent an additional 4,000 cancer cases per year, according to the research.
The study, utilizing the Iowa Cancer Registry’s Residual Tissue Repository and other U.S. registries, was recently selected by the American Society of Clinical Oncology for inclusion in Clinical Cancer Advances 2016, the society’s annual review of progress against cancer and emerging trends in the field. The full report is available on the ASCO website and also is published online in the Journal of Clinical Oncology at http://www.jco.org